In making that assumption and not contacting a trial lawyer, many employees lose out on the potential to be fully compensated for their injuries
Its robust evidence base across the STEP, SUSTAIN, and SELECT trial programs established incretin mimetics as the dominant pharmacologic class for obesity
This documentation serves multiple purposes
NAEs were identified using SOC = nervous system disorders (SOC ID: 10,029,205) and primary SOC = Yes, encompassing 1075 PTs from MedDRA version 27.0
If you attempt discontinuation, decide in advance what weight regain threshold will trigger medication resumption
This study population was then divided into two cohorts: (1) Semaglutide cohort 45,445 patients prescribed semaglutide, and (2) non-GLP1-RA anti-obesity medication cohort 37,744 patients prescribed non-GLP-1RA anti-obesity medications but not semaglutide